Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745324 | 0.90 | ESR1 (0.45) | ESR1ESR2ABHD6DRD1DRD2 | |
| SCHEMBL31121185 | 0.90 | ESR1 (0.45) | ESR1ESR2ABHD6DRD1DRD2 | |
| SCHEMBL1095022 | 0.87 | ESR1 (0.45) | ESR1ESR2DRD1DRD2DRD5 | |
| SCHEMBL1094863 | 0.87 | HTR2A (0.47) | ESR1ESR2ABHD6DRD1CYP11B2 | |
| SCHEMBL30012797 | 0.87 | HTR2A (0.47) | ESR1ESR2ABHD6DRD1CYP11B2 | |
| SCHEMBL1095978 | 0.84 | ESR1 (0.42) | ESR1ESR2ABHD6DRD1DRD2 | |
| SCHEMBL1094406 | 0.84 | HTR2A (0.48) | ESR1ESR2DRD1DRD5 | |
| SCHEMBL1094266 | 0.81 | HTR2A (0.48) | ESR1ESR2 | |
| SCHEMBL31121204 | 0.81 | ESR1 (0.49) | ESR1ESR2DRD2HTR1ADRD3 | |
| SCHEMBL3282297 | 0.81 | ESR1 (0.49) | ESR1ESR2DRD2HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | ESR1 1181/4885ESR2 456/4885ABHD6 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.